ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "E126: Risk Signals, JAKs, and SELECTIVE-ity"
Episode Synopsis
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published
Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
More episodes of the podcast The Evidence Based Rheumatology Podcast
E127: TNFs and All That CHF
22/09/2025
E122: Guidelines for Maybe Diagnosing HLH
17/04/2025
E121: Obinutuzumab in SLE-LN
02/04/2025
E120: Real Life Use of PEXIVAS-Low
06/03/2025
In God we trust